Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferinject for Thrombocytosis in IBD
NCT00882414Phase 2Terminated
- Sponsor
- CSL Vifor
- Start
- Dec 2006
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ferric carboxymaltose in thrombocytosis and iron deficiency anemia (IDA) (4 arms), sponsored by CSL Vifor. Primary endpoint: Efficacy of FERINJECT in reducing elevated platelet counts at 6 weeks. Started Dec 2006; status: terminated.
02
Drugs
ferric carboxymaltose
03
Conditions
thrombocytosisiron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT00882414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00882414.